Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

被引：64
作者：
van Vollenhoven, Ronald F. [1 ]
机构：
[1] Karolinska Univ Hosp, S-17176 Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷 / 07期
关键词：
D O I：
10.1136/ard.2007.069872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：849 / 851
页数：3
相关论文
共 26 条
  • [11] Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
    Furst, Daniel E.
    Gaylis, Norman
    Bray, Vance
    Olech, Ewa
    Yocum, David
    Ritter, Jeffrey
    Weisman, Michael
    Wallace, Daniel J.
    Crues, John
    Khanna, Dinesh
    Eckel, Gregory
    Yeilding, Newman
    Callegari, Peter
    Visvanathan, Sudha
    Rojas, Jeannie
    Hegedus, Ronald
    George, Laura
    Mamun, Khalid
    Gilmer, Keith
    Troum, Orrin
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) : 893 - 899
  • [12] Gómez-Puerta JA, 2004, ANN RHEUM DIS, V63, P896
  • [13] Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
    Gomez-Reino, JJ
    Carmona, L
    [J]. ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)
  • [14] Hansen KE, 2004, J RHEUMATOL, V31, P1098
  • [15] Haraoui B, 2004, J RHEUMATOL, V31, P2356
  • [16] HJARDEM E, 2007, ANN RHEUM DIS
  • [17] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Silman, Alan J.
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (01): : 13 - 20
  • [18] Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
    Iannone, Florenzo
    Trotta, Francesco
    Monteccuco, Carlomaurizio
    Giacomelli, Roberto
    Galeazzi, Mauro
    Matucci-Cerinic, Marco
    Ferri, Clodoveo
    Cutolo, Maurizio
    Bambara, Lisa Maria
    Triolo, Giovanni
    Ferraccioli, Gianfranco
    Valentini, Gabriele
    Lapadula, Giovanni
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) : 249 - 252
  • [19] Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
    Nikas, SN
    Voulgari, PV
    Alamanos, Y
    Papadopoulos, CG
    Venetsanopoulou, AI
    Georgiadis, AN
    Drosos, AA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) : 257 - 260
  • [20] Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody
    Solau-Gervais, E.
    Laxenaire, N.
    Cortet, B.
    Dubucquoi, S.
    Duquesnoy, B.
    Flipo, R.-M.
    [J]. RHEUMATOLOGY, 2006, 45 (09) : 1121 - 1124
123